Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned a consensus rating of “Moderate Buy” from the eighteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $57.8235.

RARE has been the topic of a number of recent analyst reports. Barclays lowered their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Wedbush dropped their price target on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Wells Fargo & Company cut their price target on shares of Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Finally, Cantor Fitzgerald lifted their target price on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, May 21st.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Shehnaaz Suliman sold 5,740 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $25.12, for a total transaction of $144,188.80. Following the completion of the transaction, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. This represents a 17.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. This trade represents a 1.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 14,292 shares of company stock valued at $351,644. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth about $15,717,000. Focus Partners Advisor Solutions LLC acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $327,000. GSA Capital Partners LLP purchased a new position in Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $406,000. Oppenheimer Asset Management Inc. purchased a new position in Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $221,000. Finally, Handelsbanken Fonder AB boosted its holdings in shares of Ultragenyx Pharmaceutical by 17.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 39,523 shares of the biopharmaceutical company’s stock worth $1,320,000 after purchasing an additional 6,000 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Up 3.6%

Ultragenyx Pharmaceutical stock opened at $25.82 on Friday. The firm has a market cap of $2.54 billion, a PE ratio of -4.42 and a beta of 0.35. Ultragenyx Pharmaceutical has a 12 month low of $18.29 and a 12 month high of $39.89. The stock’s 50 day simple moving average is $27.85 and its two-hundred day simple moving average is $24.79.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.32. The firm had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business’s revenue was up 28.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.17) EPS. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post -4.53 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.